RxDoctor Payments Data

Subhankar Chakraborty, MD

Gastroenterology · Columbus, OHNPI 1851685812

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,892 of the $6,502 with a category attached, or 75.2%. Sanofi accounts for 75.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $4,701 and has fallen 99.7% since, to $16 in 2025.

$6,502in general payments, 2019–2025

Across 9 payments — averaging $722.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Neuraxis, Inc.$155
  • Coloplast$85
  • Medtronic$55
  • Exact Sciences$28
  • plus $37 from 2 others
$285,411in research payments, 2019–2025

Across 47 payments — averaging $6072.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vanda Pharmaceuticals Inc.$191K
  • Regeneron$47K
  • Medtronic$47K

What the payments were for

  • Consulting fees$4,89275%
  • Speaking & faculty fees$1,25019%
  • Food & beverage$3445%
  • Education$160%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,502 in reported general payments places this provider in the 70th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$55,928
Medicare patients
282
Services billed
503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aprepitant50$258,717
LinzessLinaclotide56$44,942
CreonLipase/Protease/Amylase11$29,530
ErythromycinErythromycin Base29$23,907
MotegrityPrucalopride Succinate23$23,450
Esomeprazole Magnesium19$4,013
Pantoprazole Sodium97$2,842
Lactated RingersRinger's Solution,lactated38$2,004
Lansoprazole63$1,533
Omeprazole81$1,524
Sucralfate18$1,348
Famotidine85$1,199
Lubiprostone12$1,152
Amitriptyline Hcl70$1,076
Ondansetron OdtOndansetron42$1,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$16$23,45023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 657 gastroenterology providers in Ohio.

Other gastroenterology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →